Sunovion names new CEO

Photo/Grant Welker Marlborough's Sunovion is developing a drug to treat adult schizophrenia and is encouraged by test results.

Photo | Courtesy Anthony Loebel

Write a Comment

Marlborough drugmaker Sunovion Pharmaceuticals has named its executive vice president and medical chief as its new CEO beginning next month.

Anthony Loebel will take over for Nobuhiko Tamura beginning April 1. Tamura, the company’s leader since 2014, will assume new responsibilities including executive director of compliance and quality assurance in Sumitomo Dainippon Pharma Co., Ltd., Sunovion’s parent company.

Loebel joined the parent organization in 2007 after seven years in senior leadership roles at Pfizer. He has served as an executive leadership team member at Sunovion and as executive officer of Sumitomo.

In a press release, the company credits Loebel with the company’s strategic direction and leadership in R&D, including overseeing clinical development and directing initiatives to address unmet medical needs.

Lobel is a board-certified psychiatrist, a clinical assistant professor of psychiatry at New York University School of Medicine, a fellow of the American Psychiatric Association and member of the American College of Neuropsychopharmacology. He earned his M.D. from the University of Washington School of Medicine in Seattle.

He holds an award in leadership from the International Society for CNS Drug Development